Wednesday, July 8, 2026

Patent intelligence · US

US 8080526

Methods and compositions for the treatment of gastrointestinal disorders

granted A61KA61K38/00A61PA61P1/00
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 5
Applicant portfolio 45
Patent details — US 8080526
Jurisdiction
US
Status
granted
Grant date
Dec 20, 2011
Expiration
Dec 15, 2031
Claims
2
CPC classes
A61K, A61K38/00, A61P, A61P1/00
View on Google Patents ↗

Quick answer

US 8080526 (Methods and compositions for the treatment of gastrointestinal disorders) is held by IRONWOOD PHARMACEUTICALS, INC.. Status: granted. Granted Dec 20, 2011. Expires Dec 15, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
2
CPC classes
A61K, A61K38/00, A61P, A61P1/00, A61P1/04, A61P1/08

More from IRONWOOD PHARMACEUTICALS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 10702576

    Stable formulations of linaclotide

    IRONWOOD PHARMACEUTICALS, INC. · Expires Jul 2, 2040

    granted
  2. US 10675325

    Stable formulations of linaclotide

    IRONWOOD PHARMACEUTICALS, INC. · Expires Jun 4, 2040

    granted
  3. US 10618938

    Compositions for colon cleansing and the treatment of gastrointestinal disorders

    IRONWOOD PHARMACEUTICALS, INC. · Expires Apr 9, 2040

    granted
  4. US 10266529

    Salts, co-crystals, and polymorphs of an anxiolytic compound

    IRONWOOD PHARMACEUTICALS, INC. · Expires Apr 18, 2039

    granted
  5. US 10189809

    SGC stimulators

    IRONWOOD PHARMACEUTICALS, INC. · Expires Jan 24, 2039

    granted
  6. US 10183021

    sGC stimulators

    IRONWOOD PHARMACEUTICALS, INC. · Expires Jan 17, 2039

    granted
  7. US 10047095

    sGC stimulators

    IRONWOOD PHARMACEUTICALS, INC. · Expires Aug 9, 2038

    granted
  8. US 9969742

    Imidazotriazinone compounds

    IRONWOOD PHARMACEUTICALS, INC. · Expires May 10, 2038

    granted

Frequently asked questions

What is US patent 8080526?

US 8080526 (Methods and compositions for the treatment of gastrointestinal disorders) is held by IRONWOOD PHARMACEUTICALS, INC.. Status: granted. Granted Dec 20, 2011. Expires Dec 15, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8080526?

IRONWOOD PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 45 pharmaceutical patents for this assignee.

When does US 8080526 expire?

Our index shows an expiration date of Dec 15, 2031 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.